Reduced mobility of fibroblast growth factor (FGF)-deficient myoblasts might contribute to dystrophic changes in the musculature of FGF2/FGF6/mdx triple-mutant mice

被引:62
|
作者
Neuhaus, P
Oustanina, S
Loch, T
Krüger, M
Bober, E
Dono, R
Zeller, R
Braun, T
机构
[1] Univ Halle Wittenberg, Inst Physiol Chem, D-06097 Halle An Der Saale, Germany
[2] Univ Utrecht, Dept Dev Biol, NL-3584 Utrecht, Netherlands
关键词
D O I
10.1128/MCB.23.17.6037-6048.2003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Development and regeneration of muscle tissue is a highly organized, multistep process that requires cell proliferation, migration, differentiation, and maturation. Previous data implicate fibroblast growth factors (FGFs) as critical regulators of these processes, although their precise role in vivo is still not clear. We have explored the consequences of the loss of multiple FGFs (FGF2 and FGF6 in particular) for muscle regeneration in mdx mice, which serve as a model for chronic muscle damage. We show that the combined loss of FGF2 and FGF6 leads to severe dystrophic changes in the musculature. We found that FGF6 mutant myoblasts had decreased migration ability in vivo, whereas wild-type myoblasts migrated normally in a FGF6 mutant environment after transplantation of genetically labeled myoblasts from FGF6 mutants in wild-type mice and vice versa. In addition, retrovirus-mediated expression of dominant-negative versions of Ras and Ral led to a reduced migration of transplanted myoblasts in vivo. We propose that FGFs are critical components of the muscle regeneration machinery that enhance skeletal muscle regeneration, probably by stimulation of muscle stem cell migration.
引用
收藏
页码:6037 / 6048
页数:12
相关论文
共 9 条
  • [1] Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice
    Miller, DL
    Ortega, S
    Bashayan, O
    Basch, R
    Basilico, C
    MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (06) : 2260 - 2268
  • [2] Basic fibroblast growth factor (FGF2) gene polymorphisms could contribute to SSRIs treatment response and tolerability
    Kato, M.
    Okugawa, G.
    Wakeno, M.
    Takekita, Y.
    Nounen, S.
    Tetsuo, S.
    Azuma, J.
    Serretti, A.
    Kinoshita, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S405 - S406
  • [3] Oligodendrocyte lineage cell populations during myelination and remyelination in fibroblast growth factor (FGF2) knockout mice
    Armstrong, RC
    Le, TQ
    Vana, AC
    Murtie, JC
    JOURNAL OF NEUROCHEMISTRY, 2001, 78 : 28 - 28
  • [4] Limb functional recovery is impaired in fibroblast growth factor-2 (FGF2) deficient mice despite chronic ischaemia-induced vascular growth
    Adeyemo, Adeola
    Johnson, Christopher
    Stiene, Andrew
    LaSance, Kathleen
    Qi, Zhihua
    Lemen, Lisa
    Schultz, Jo El J.
    GROWTH FACTORS, 2020, 38 (02) : 75 - 93
  • [5] Reduced Axonopathy and Enhanced Remyelination After Chronic Demyelination in Fibroblast Growth Factor 2 (Fgf2)-Null Mice: Differential Detection With Diffusion Tensor Imaging
    Tobin, Jennifer E.
    Xie, Mingqiang
    Le, Tuan Q.
    Song, Sheng-Kwei
    Armstrong, Regina C.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2011, 70 (02): : 157 - 165
  • [6] Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice (vol 20, pg 2260, 2000)
    Miller, DL
    Ortega, S
    Bashayan, O
    Basch, R
    Basilico, C
    MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (10) : 3752 - 3752
  • [7] Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor-Deficient Mice
    Omar, Bilal A.
    Andersen, Birgitte
    Hald, Jacob
    Raun, Kirsten
    Nishimura, Erica
    Ahren, Bo
    DIABETES, 2014, 63 (01) : 101 - 110
  • [8] Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice
    Katsouri, Loukia
    Ashraf, Azhaar
    Birch, Amy M.
    Lee, Kevin K. L.
    Mirzaei, Nazanin
    Sastre, Magdalena
    NEUROBIOLOGY OF AGING, 2015, 36 (02) : 821 - 831
  • [9] Sca-1+ Cell-Based Gene Therapy with a Modified Fibroblast Growth Factor 2 (FGF2) Increased Endosteal/Trabecular Bone Formation in Mice
    Hall, Susan L.
    Lau, K. -H. William
    Chen, Shin-Tai
    Sheng, Matilda H. -C.
    Srivastava, Apurva K.
    Klamut, Henry J.
    Wergedal, Jon E.
    Gridley, Daila S.
    Mohan, Subburaman
    Baylink, David J.
    MOLECULAR THERAPY, 2006, 13 : S173 - S173